首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Cardiac mast cell–derived renin promotes local angiotensin formation norepinephrine release and arrhythmias in ischemia/reperfusion
【2h】

Cardiac mast cell–derived renin promotes local angiotensin formation norepinephrine release and arrhythmias in ischemia/reperfusion

机译:心肌肥大细胞来源的肾素可促进局部血管紧张素形成去甲肾上腺素释放和缺血/再灌注中的心律不齐

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Having identified renin in cardiac mast cells, we assessed whether its release leads to cardiac dysfunction. In Langendorff-perfused guinea pig hearts, mast cell degranulation with compound 48/80 released Ang I–forming activity. This activity was blocked by the selective renin inhibitor BILA2157, indicating that renin was responsible for Ang I formation. Local generation of cardiac Ang II from mast cell–derived renin also elicited norepinephrine release from isolated sympathetic nerve terminals. This action was mediated by Ang II-type 1 (AT1) receptors. In 2 models of ischemia/reperfusion using Langendorff-perfused guinea pig and mouse hearts, a significant coronary spillover of renin and norepinephrine was observed. In both models, this was accompanied by ventricular fibrillation. Mast cell stabilization with cromolyn or lodoxamide markedly reduced active renin overflow and attenuated both norepinephrine release and arrhythmias. Similar cardioprotection was observed in guinea pig hearts treated with BILA2157 or the AT1 receptor antagonist EXP3174. Renin overflow and arrhythmias in ischemia/reperfusion were much less prominent in hearts of mast cell–deficient mice than in control hearts. Thus, mast cell–derived renin is pivotal for activating a cardiac renin-angiotensin system leading to excessive norepinephrine release in ischemia/reperfusion. Mast cell–derived renin may be a useful therapeutic target for hyperadrenergic dysfunctions, such as arrhythmias, sudden cardiac death, myocardial ischemia, and congestive heart failure.
机译:在心脏肥大细胞中鉴定出肾素后,我们评估了其释放是否会导致心脏功能障碍。在Langendorff灌注的豚鼠心脏中,肥大细胞脱粒与化合物48/80释放了Ang I形成活性。该活性被选择性肾素抑制剂BILA2157阻断,表明肾素负责Ang I的形成。肥大细胞来源的肾素可局部产生心脏Ang II,也会引起去甲肾上腺素从孤立的交感神经末梢释放。此作用是由Ang II型1(AT1)受体介导的。在使用Langendorff灌注的豚鼠和小鼠心脏的2种缺血/再灌注模型中,观察到了肾素和去甲肾上腺素的明显冠脉外溢。在这两种模型中,都伴有心室纤颤。用cromolyn或lodoxamide稳定肥大细胞可显着减少活性肾素溢流,并减弱去甲肾上腺素释放和心律不齐。在用BILA2157或AT1受体拮抗剂EXP3174治疗的豚鼠心脏中观察到类似的心脏保护作用。在缺乏肥大细胞的小鼠心脏中,缺血/再灌注中的肾素溢流和心律不齐的情况远不如对照心脏。因此,肥大细胞来源的肾素对于激活心脏肾素-血管紧张素系统至关重要,从而导致缺血/再灌注过程中去甲肾上腺素释放过多。肥大细胞源性肾素可能是治疗高肾上腺素功能障碍(例如心律不齐,心源性猝死,心肌缺血和充血性心力衰竭)的有用治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号